Btg
As of the edition of 20 October 2026, Btg runs 5 drugs, 5 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Iloprost | none listed | 1 |
| Glucarpidase | Ended 2024 (computed from the first US licence) | 0 |
| Hydroxocobalamin | none listed | 0 |
| Technetium | none listed | 0 |
| Uridine triacetate | none listed | 0 |
A route B row is one company at one target.